Archive | Redefining Early Stage Investments RSS feed for this section

RESI Philadelphia: Check Out the Program Guide Now

30 May

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

The next Redefining Early Stage Investments (RESI) conference is right around the corner, and we are excited to release the digital program guide in anticipation of the event! The RESI conference was created to bring early-stage companies together with early stage investors and strategic channel partners. The theme is to maximize the capability of ­finding partners who are a ­fit for the stage of development and product of a fi­rm. With attendance close to venue capacity and meetings slots filling up, there are many opportunities to make successful connections, for investors, channel partners and startups.

Seeking funding for life science companies comes with multiple challenges. First, there is an abundance of early-stage companies seeking capital in the US and globally, as a result of immense governmental R&D support at life science technology hubs around the world. These companies, whether university spin-outs or independently founded, ­find themselves competing for a limited amount of regional capital, and many of them require strategic advice to help launch and stage a successful global fundraising campaign.

Second, it can be extremely dif­ficult to ­find and get in front of the active investors in the space, be they angels, family of­fices, VCs, PE, or Pharma. This is often due to the sheer volume of deal opportunities in their inbox, making it hard for the startup to differentiate itself. Compounding the early stage funding dynamic is the lack of a public face for many family of­fices, most choosing to be in stealth mode under the radar screen, posing yet another challenge to getting in front of the right investor.

What’s unique about RESI is that the event is cross border and cross domain. RESI focuses squarely on connecting startups with 10 categories of global investors across the silos of Drugs, Devices, Diagnostics and Digital Health, the “4 Ds”. RESI caters to both the earliest stage startups, those seeking grants, seed and angel capital, and the early stage firms who seek series A and B funding. Because LSN organizes a RESI conference every few months, fundraising CEOs and investment partners can incorporate RESI into their monthly global business activities.

Take a look at the RESI Philadelphia program guide to see the content scheduled, including an amazing line up of panelists, as well as the exciting companies participating in the Innovation Challenge and Innovators’ Pitch Challenge. See you next week!

LSN-KOTRA Partnership: Introducing Promising Technologies from South Korea

30 May

By Claire Jeong, Director of Research, Asia BD, LSN

claireOur next Redefining Early Stage Investments (RESI) Conference in Philadelphia is now just 4 days away, and is anticipated to be our largest RESI held concurrent with the BIO International Convention. A few weeks ago, I covered LSN’s partnership with the Korea Trade-Investment Promotion Agency (KOTRA) and supporting organizations to bring a large delegation of startup companies from South Korea, similar to what we have done at last year’s RESI around BIO. We believe that all 10 participating companies have strong potential to scale and are fully capable of engaging with global investors and strategic partners. Some of these companies were selected to participate in the RESI Innovation Challenge and will be exhibiting posterboards of their technology throughout the entire day, and select others will be presenting short company pitches to a panel of active life science industry professionals during the “Korea Pitch Challenge” session from 11:00 – 11:50 am. We hope you will have the chance to meet some of these companies at RESI next week!

Participating Companies:

Orum Therapeutics (OT)

Orum Therapeutics (OT) is a biotech company with offices in Daejeon, Korea and Cambridge, Massachusetts. OT developed cell-penetrating antibodies that can access the cytosol of living cells following receptor-mediated endocytosis. This will enable producing next-generation therapeutic antibodies that directly target cytosolic proteins, which are associated with many untreatable or difficult-to-treat human diseases including cancer and other rare diseases. OT can engineer various therapeutic antibodies capable of entering the cytosol. Because OT’s fully human antibodies do not require chemical conjugation or formulation for delivery, their manufacturing procedures are similar to those used for any therapeutic monoclonal antibody. OT’s antibodies can be engineered to specifically bind different cell-surface receptors to enhance targeting to specific tissues.


NEXEL focuses on biotherapeutic development where candidates are derived from internal stem cell-based research. Using its expertise in stem cell, NEXEL also provides highly pure and functional iPSC-derived cell products. NP-011, a pre-clinical stage anti-fibrotic recombinant protein, has a potent anti-fibrotic activity. It has demonstrated its efficacy in NASH, IPF, MI animal models and has demonstrated an excellent safety profile in a 4-week multi-tox study. NEXEL offers iPSC-derived cardiomyocytes, neurons, and hepatocytes for drug discovery and development activities.

Genesen Inc.

Genesen Inc. is developing peptide-based new drugs that selectively inhibit toll-like receptors (TLRs), to treat autoimmune diseases. Computational simulation and phage display are used to discover peptide candidates, followed by secondary structure prediction and molecular dynamics simulation to optimize the peptide sequence. The experienced Genesen team is aimed not only to develop the first-in-class peptide drug to cure lupus patients, but also to expand to other immune diseases such as rheumatoid arthritis, IBD, Psoriasis and Multiple sclerosis.

Soundable Health

Soundable Health is a digital health company with leading sound AI technology. Our mission is to help people to understand and manage their health and diseases easily to live with dignity. Our first product, PRIVY™, is a mobile app that records the sound of the urine stream on the smartphone at the bathroom and turns it into clinical-grade urine flow exam results for prostate and bladder patients and their physicians Through alpha and beta test we launched the open-beta app in the US and Korea and have collected over 4000 actual measurement data and results from users and physicians.


Shaperon is a biotech company navigating in the universe of immunology and inflammation. Their flagship compounds are TGR5 agonists, the first of its kind developed for inflammatory diseases such as atopic dermatitis, ulcerative colitis, sepsis, and Alzheimer’s disease. TGR5 receptor as signal transduction modulator is the optimal target for inflammatory diseases where immune homeostasis is critically damaged due to multiple factors and its restoration requires global regulation of immune cell interactions.

Genome Opinion

Genome Opinion‘s goal is to integrate genomic and health data to develop novel technologies to improve human health. The Company was co-founded by a medical doctor from Seoul National University Hospital and researchers from Genome Analytics of Samsung Group in 2017 – together, our team has +30 years’ experience of genomic data analytics. We are currently focusing on integrating NGS based in-vitro diagnostic test results and longitudinal health record data, in order to predict and diagnose risks related to cardiovascular diseases and cancers. The Company launched a study on inherited risk related to cardiovascular diseases by conducting analysis on ~36,000 samples from Korea Biobank. We have also formed a strategic alliance with a health checkup clinic in Korea to conduct cardiovascular disease related risk analysis on ~5,000 personnel.


BIO3S is a research-oriented startup launched in 2016 with its mission to benefit life for humans by uncovering host defense mechanism against virus infections. Based on big data analysis obtained from proteomics, metabolomics, and transcriptomics, BIO3S developed two core bioconversion technologies: (1) producing mannunnorate oligosaccharide from seaweed alginate using safe bacterial enzyme, and (2) developing oncolytic virus using virus culture technology.

Tomocube, Inc.

Tomocube, Inc. is a high-tech startup with optical diffraction tomography and DMD technology. Opening a new era for microscopy, Tomocube’s revolutionary 3D holographic microscopy technique makes it possible to take 3D images of live cells without using fluorescent probes which may cause severe phototoxicity and require time-consuming preparation steps. Its products are actively used in Harvard Medical School, MIT, UPMC, and other leading institutions.


NuriBio has vigorously focused on research and development of PCR-based genetic analysis tools, resulting in proprietary technology that outperforms its’ competitors. NuriBio’s PROMER™ tech is composed of DNA-RNA-DNA structure and performs primer and probe function simultaneously, unlike primer and probe system consisting only of DNA. RNase H enzyme, which degrades the RNA-DNA structure within PROMER, is added and only when the PROMER RNA site binds precisely to the target gene, the RNA-DNA structure is degraded and amplification begins. Therefore, only the target gene can be selectively amplified, so that it is possible to realize high performance with low cost without additional experiments with fewer components.

IH Bio

IH Bio’s cancer immunotherapy (IH002B) is a monoclonal antibody therapy that induces complete remission (CR) in the most advanced metastatic pancreatic ductal adenocarcinoma as well as in a wide range of tumors at much lower concentrations. It has also been reported to induce CR in end-stage cancer. Histologically, the process involves fibrotic encapsulation of the tumor and creation of a space between the normal and cancerous tissues to induce spontaneous tumor resection, thus completely preventing tumor growth, motility, invasion, and metastasis.

Sponsoring Organizations:

Korea Trade-Investment Promotion Agency (KOTRA): KOTRA is a Korean government agency dedicated to promoting international trade and investment, drive the nation’s economic development, and build prosperity for the global community. Through its 129 offices in 84 countries, KOTRA serves small and medium-sized Korean enterprises looking to tap into the overseas markets. Cultivating innovation and building a vibrant, sustainable startup ecosystem is key to reaching the next stage of Korea’s economic growth. To that end, KOTRA is committed in mentoring rising startup companies and providing institutional support to facilitate their continued success.

Korea Biotechnology Industry Organization (KoreaBIO): Korea Biotechnology Industry Organization (KoreaBIO) emerged in 2008 following the merger of three biotechnology industry associations in Korea. Representing over 300 corporate members from the pharmaceutical and biotechnology sectors, KoreaBIO offers training programs and policy advocacy roles to improve the regulatory climate, promote R&D investments, and facilitate global partnerships.

Bluepoint Partners: Bluepoint Partners is a partnership-driven startup accelerator and an early stage VC fund that concentrates on bridging talented high-tech entrepreneurs with real global solutions.  As champions of progressive startups, BP’s partners and expert mentors work hand-in-hand with entrepreneurs enabling them to build a viable business, make connections, raise capital, seek growth, and fulfill their vision.

Korea Institute of Marine Science & Technology Promotion (KIMST): Since 2006, the Korea Institute of Marine Science & Technology Promotion (KIMST) has led the nation’s marine science research and ocean management planning initiatives. KIMST develops and implements national marine policies, establishes ocean planning strategies and systems to maximize productivity, and drives future growth by putting research results to practical use.

Look Who You Can Meet at RESI Philadelphia on Monday

30 May

By Lucy Parkinson, VP of Investor Research, LSN

RESI is imminently arriving in Philly, bringing hundreds of life science investors dedicated to early stage investments together in one venue to meet with biotech, medtech, diagnostics and digital health CEOs.  RESI Partnering is still in full swing, with many hundreds of meetings booked and hundreds more still to come.  If you’re looking to meet investors and raise capital, see below for the firms and funds you can connect with at RESI Philadelphia.  We are looking forward to seeing you there in just a few days!

Confirmed RESI Philly Investors

And More…

%d bloggers like this: